Alpha-9 Oncology
Katherine Li is a highly experienced professional in business development and strategy, with a background in private equity and investment banking. Katherine has worked with companies such as Alpha-9 Oncology, Flagship Pioneering, Cerevel Therapeutics, Pfizer, and Court Square Capital Partners. Katherine holds a Master of Business Administration from MIT Sloan School of Management and a Bachelor of Science in Finance from The Wharton School, as well as a Bachelor of Arts in Biology from the University of Pennsylvania.
This person is not in any teams
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.